8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2020

Protara Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

Delaware	001-36694	20-4580525
(State or other jurisdiction of incorporation)	(Commission File No.)	(IRS Employer Identification No.)

1 Little West 12th Street New York, NY	10014
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code: (646) 844-0337

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	TARA	The Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On September 8, 2020, Protara Therapeutics, Inc. (the “Company”) issued a press release entitled “Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications,” a copy of which is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01, including Exhibit 99.1, is being furnished pursuant to Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall the information be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 8.01 Other Events.

On September 8, 2020, the Company made available a Corporate Presentation on the Investor Relations page of the Company’s website, which will be used at investor and other meetings. A copy of the Corporate Presentation is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and is incorporated herein by reference. The Company does not undertake to update this presentation.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Exhibit Description
99.1	Press Release, dated September 8, 2020.
99.2	Protara Therapeutics, Inc. Corporate Presentation, September 2020.

1 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Protara Therapeutics, Inc.
Dated: September 8, 2020	By:	/s/ Blaine Davis
		Blaine Davis
		Chief Financial Officer

2

EX-99.1

Exhibit 99.1

 

Protara Therapeutics Provides Comparability and U.S. Regulatory Updates for TARA-002 Supporting Advancement in Oncology and Rare Disease Indications

- Company Demonstrates Initial Comparability Between TARA-002 and OK-432, Advancing to Final GMP Comparability Runs -

- Reaches Alignment with FDA on Development Path Forward for TARA-002 in Non-Muscle Invasive Bladder Cancer; Company Plans to Initiate Clinical Trials in 2021 -

- Company Expects to Request Meeting with FDA by Year End to Discuss Path to BLA for TARA-002 in Lymphatic Malformations -

NEW YORK, September 8, 2020 - Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases with significant unmet needs, today announced its development plans for TARA-002 in both non-muscle invasive bladder cancer (NMIBC) and Lymphatic Malformations (LMs) following recent interactions with the U.S. Food and Drug Administration (FDA). TARA-002 is the Company’s lead investigational cell therapy based on the broad immunopotentiator OK-432, which is approved in Japan and Taiwan for the treatment of LMs and multiple oncologic indications.

“The outcome of our recent interaction with the FDA represents a significant milestone for the TARA-002 program, confirming initial comparability between TARA-002 and OK-432 and expanding the potential market opportunity of TARA-002 beyond LMs to include a potentially significant oncology indication,” said Jesse Shefferman, Chief Executive Officer of Protara Therapeutics. “Importantly, we believe that we have identified an efficient path forward that allows us to address the population of patients suffering from NMIBC who are lacking alternative therapeutic options. Patients suffering from NMIBC have limited approved treatment options, and with the current standard-of-care facing a historical long-term supply shortage, there is a dire need for novel and effective therapies for these patients.”

Mr. Shefferman added, “In addition to the opportunity in NMIBC, as we near completion of our IND update and make progress toward finalizing GMP comparability of TARA-002 to OK-432, we continue to expect to request a meeting with the FDA by year end to discuss a potential near-term path to a BLA filing for TARA-002 in LMs. TARA-002 was recently granted a Rare Pediatric Disease Designation for LMs, a rare pediatric indication with an urgent need for new therapeutic approaches.”

FDA Confirmed Initial Comparability Between TARA-002 and OK-432; Final GMP Comparability Expected to be Completed in Mid-2021

Following a recent pre-Investigational New Drug (IND) engagement with the Office of Tissues and Advanced Therapies division of the Center for Biologics Evaluation and Research (CBER), the FDA agreed that Protara has successfully demonstrated initial manufacturing comparability between TARA-002 and OK-432 and that the Company was on track with its plans to conduct three large-scale batch runs to confirm comparability. Good Manufacturing Practice (GMP) scale up is currently in process and the Company will initiate GMP comparability runs with an expected completion date in mid-2021.

 

Clinical Development Path in NMIBC

In addition, the Company reached alignment with the FDA on a proposed clinical development plan to evaluate TARA-002 in patients with NMIBC. Advancement into the clinic will be supported by existing and ongoing non-clinical studies as well as the historical safety and efficacy data for OK-432.

Subject to the successful completion of select non-clinical studies to characterize local toxicity of intravesical administration of TARA-002 as well as acceptance of an IND filing, the Company plans to commence a Phase 1 study in 2021 to assess the safety and tolerability of TARA-002 in patients with NMIBC, including patients with carcinoma in situ (CIS), with results expected in 2022.

The Phase 2 development program, which Protara plans to commence in 2022, is expected to include NMIBC patients with CIS +/- Ta and/or T1 papillary tumors and high-grade Ta and/or T1 papillary tumors without CIS.

Regulatory Path in LMs

Protara plans to request a meeting with the FDA Division of Vaccines and Related Products Applications by year end to discuss the regulatory path for TARA-002 in LMs. The Company plans to utilize the robust dataset for OK-432 in LMs to support a Biological License Application (BLA) filing for TARA-002 in LMs. In a randomized, Phase 2 clinical trial of OK-432 in LMs conducted in the U.S., 68% of patients treated with OK-432 (>90% pediatric) in the immediate treatment group experienced a complete or substantial response. Long-term control of LMs was favorable, with more than 90% of patients treated with OK-432 having no regrowth over a median follow-up period of approximately three years following treatment.

About TARA-002

TARA-002 is an investigational cell therapy in development for the treatment of lymphatic malformations (LMs) and non-muscle invasive bladder cancer (NMIBC). TARA-002 was developed from the same master cell bank of genetically distinct group A Streptococcus pyogenes as OK-432, a broad immunopotentiator marketed as Picibanil^® in Japan and Taiwan by Chugai Pharmaceutical Co., Ltd. Protara successfully demonstrated initial manufacturing comparability between TARA-002 and OK-432.

When TARA-002 is administered, it is hypothesized that innate and adaptive immune cells within the cyst or tumor are activated and produce a strong immune cascade. Neutrophils, monocytes and lymphocytes infiltrate the abnormal cells and various cytokines, including interleukins IL-6, IL-8, IL-12, interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, and vascular endothelial growth factor (VEGF) are secreted by immune cells to induce a strong local inflammatory reaction and destroy the abnormal cells. TARA-002 has been granted Rare Pediatric Disease Designation by the U.S. Food and Drug Administration for the LMs indication.

2

 

About Non-Muscle Invasive Bladder Cancer

Bladder cancer is the 6th most common cancer in the United States, with non-muscle invasive bladder cancer (NMIBC) representing approximately 80% of bladder cancer diagnoses. Approximately 65,000 patients are diagnosed with NMIBC in the United States each year. NMIBC is cancer found in the tissue that lines the inner surface of the bladder that has not spread into the bladder muscle. The current standard of care for high-grade NMIBC includes intravesical Bacillus Calmette-Guerin (BCG), which has been the subject of multiple global supply shortages in the past decade.

About Lymphatic Malformations

Lymphatic malformations (LMs) are rare, congenital malformations of lymphatic vessels resulting in the failure of these structures to connect or drain into the venous system. Most LMs present in the head and neck region and are diagnosed in early childhood during the period of active lymphatic growth, with more than 50% detected at birth and 90% diagnosed before the age of 2 years. The most common morbidities and serious manifestations of the disease include compression of the upper aerodigestive tract, including airway obstruction requiring intubation and possible tracheostomy dependence; intralesional bleeding; impingement on critical structures, including nerves, vessels, lymphatics; recurrent infection, and cosmetic and other functional disabilities.

About Protara Therapeutics, Inc.

Protara is committed to identifying and advancing transformative therapies for people with cancer and rare diseases with limited treatment options. Protara’s portfolio includes its lead program, TARA-002, an investigational cell-based therapy being developed for the treatment of non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease. For more information, visit www.protaratx.com.

3

 

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: statements regarding Protara’s business strategy, Protara’s manufacturing and development plans for its product candidates and related interactions with the FDA. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include risks and uncertainties associated with: Protara’s development programs, including the initiation and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies; the impact of the COVID-19 pandemic on Protara’s business, clinical supply chain, clinical trials and the global economy; general market conditions; changes in the competitive landscape; changes in Protara’s strategic and commercial plans; Protara’s ability to obtain sufficient financing to fund its strategic plans and commercialization efforts; the loss of key members of management; and the risks and uncertainties associated with Protara’s business and financial condition in general, including the risks and uncertainties described more fully under the caption "Risk Factors" and elsewhere in Protara's filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. Protara undertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law.

Company Contact:

Blaine Davis
Protara Therapeutics
Blaine.Davis@protaratx.com
646-844-0337

4

EX-99.2

Exhibit 99.2

CorporatePresentation September2020

Forward Looking Statements Statements contained in this presentation regarding matters that are not historical facts are "forward looking statements" wi thin the meaning of the Private Securities Litigation Reform Act of 1995. Protara may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “designed,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words or expressions referencing future events, conditions or circumstances that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such forward-looking statements include but are not limited to, statements regarding Protara’sintentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Protara’sbusiness strategy, Protara’smanufacturing and development plans for its product candidates and related interactions with the FDA, ex-U.S. development plans, Protara’sfinancial footing, the impact of the COVID-19 pandemic and related governmental responses on Protara’sbusiness and clinical programs. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward- looking statements. Factors that contribute to the uncertain nature of the forward-looking statements include: risks that Protara’ssales, revenue, expense and other financial guidance may not be as expected, as well as risks and uncertainties associated with: Protara’sdevelopment programs, including the initiation and completion of non-clinical studies and clinical trials and the timing of required filings with the FDA and other regulatory agencies; the impact of the COVID-19 pandemic on Protara’sbusiness, clinical supply chain, clinical trials, and the global economy; general market conditions; changes in the competitivelandscape; changes in Protara’sstrategic and commercial plans; Protara’sability to obtain sufficient financing to fund its strategic plans and commercialization efforts; having to use cash in ways or on timing other than expected; the impact of market volatility on cash reserves; the loss of key members of management; and the risks and uncertainties associated with Protara’sbusiness and financial condition in general, including the risks and uncertainties described more fully under the caption "Risk Factors" and elsewhere in Protara'sfilings and reports with theUnited States Securities and Exchange Commission. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Protaraundertakes no obligation to update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as required by law. 2

3 Investment Summary Lead programs: TARA-002 in Non-Muscle Invasive Bladder Cancer (NMIBC) and Lymphatic Malformations (LMs) • Cell-based immunopotentiator • FDA confirmed initial comparability to Japanese predecessor OK-432 • NMIBC clinical development plan in place following Pre-Investigational New Drug (PIND) engagement with FDA • TARA-002/OK-432 is standard of care in Japan for LMs; completed Phase 2 study in U.S. supports treatment effect with strong safety profile Entrepreneurial team with demonstrated history of uncovering and accelerating overlooked assets Other mid-stage development programs provide diversification and additional growth potential • IV Choline in intestinal failure associated liver disease (IFALD): Completed End Of Phase 2 dialogue with FDA and aligned on Phase 3 design

4 Entrepreneurial Team with Demonstrated History of Uncovering and Accelerating Overlooked Assets Blaine Davis Chief Financial Officer • 20 years of experience in the biopharma sector • Experience in operations, finance, corporate strategy and IR • Managed growing portfolio of rare disease products >$350M of revenue at Endo • >15 years of experience in the biopharma sector • Strong track record of streamlining clinical development programs and driving successful regulatory outcomes • Instrumental in multiple successful commercial launches Jacqueline Zummo, PhD, MPH, MBA Co-founder, Senior Vice President, R&D Operations Jesse Shefferman Co-founder, Chief Executive Officer • >20 years of experience in the biopharma sector • Led Protara since inception, with the addition of two late- stage assets and the establishment of late-stage pipeline • Drove Protara’s build-out of oncology capabilities Jathin Bandari, MD Executive Director, Clinical Development • Practicing Urologic Oncologist with > 8 years of experience • Extensive clinical experience in treating patients with NMIBC • Actively engaged in the academic urologic community through nearly 50 publications, authorships, grants, and academic appointments

5 Deeply Experienced Board of Directors Luke Beshar Chairman Michael Solomon, PhD Director Barry Flannelly, PharmD, MBA Director Roger Garceau, MD Director Greg Sargen Director Richard Levy, MD Director

6 Pipeline Addresses Multiple Indications With High Unmet Need *TARA-002 Granted Rare Pediatric Disease Designation for the treatment of LMs. OK-432 Granted Orphan Drug Designation by the U.S. FDA for the treatment of LMs, which we believe is applicable under established comparability. **Granted Orphan Drug and Fast Track Designations by the U.S. FDA † Phase 1 PK study to be conducted prior to commencing Phase 3 Phase 3Phase 2Phase 1PRE-IND Pre-IND Intestinal Failure Associated Liver Disease (IFALD)** ,† HEPATOLOGY, GI, METABOLICS IV Choline Chloride for Injection – Phospholipid Substrate Replacement Vonapanitase –Recombinant Human Type 1 Elastase (phase 1 studies completed in fistula patency and PAD) IMMUNOLOGY, ONCOLOGY TARA-002 –Lyophilized, inactivated Group A Streptococcus Lymphatic Malformations (LMs)* Non-Muscle Invasive Bladder Cancer (NMIBC) OTHER

TARA-002 LYOPHILIZED, INACTIVATED GROUP A STREPTOCOCCUS PYOGENES

8 TARA-002: Cell-Based Immunopotentiator with Significant Potential ▪ TARA-002 is an investigational, genetically distinct strain of Streptococcus pyogenes that isinactivated while retaining its immune- stimulating properties ▪ TARA-002 is manufactured under GMP conditions from the same Master Cell Bank as OK-432 (1) , once one of the largest selling oncology products in Japan ▪ FDA has confirmed initial comparability between TARA-002 and OK- 432 and path forward to completion of GMP comparability ▪ Having established initial comparability to OK-432, the extensive data generated by OK-432 will help support TARA-002 ▪ Protara has worldwide rights ex-Japan & Taiwan for TARA-002/OK-432 (1) Marketed in Japan and Taiwan as Picibanil ® . Note: Manufacturing modifications reflect manufacturing to U.S. cGMP standards live cells inactivated

9 TARA-002: Mechanism of Anti-Tumor / Anti-Cystic Activity Th1 Like Anti-Tumor Cytokine Response (1) Fujimoto T., et al. J Immunol. 1997: 5619. (2) Ryoma Y, et al. Anticancer Res. 2004; 3295-3298. (3) Zhao H, et al. Microbiol. Immunol. 1994; 183-190. Multi-Cytokine Inducer (1)(2)(3) IL-2 IL-6 IL-10 IL-12 GM-CSF TNF-a IFN-? IL-8 G-CSF

• Lymphangiomas (Lymphatic Malformations) • Gastric cancer combo with chemo (post-operative) • Primary lung cancer combo with chemo • Reduction of ascites in gastrointestinal cancer • Reduction of pleural effusion in lung cancer • Unresponsive head, neck & thyroid cancer OK-432: Human Efficacy Data in Multiple Indications 10 OK-432 has been approved (ex-US) or studied in multiple indications (1) Full Prescribing Information. Chugai Pharmaceuticals. 2016 APPROVED INDICATIONS IN JAPAN (1) • Non-Muscle Invasive Bladder Cancer • Ovarian cancer • Malignant mesothelioma • Pancreatic cancer • Esophagealcancer • Oral squamous cell cancer • Hepatocellular cancer • Ranula • Thyroglossal cysts • Pleurodesis • Seroma • Symptomatic lymphocele • Auricular hematoma OK-432 CLINICAL RESEARCH CONDUCTED IN:

TARA-002: Protara’sPlanned Strategy 11 Reach agreement with FDA that TARA-002 is comparable to OK-432 Accelerate development in LMs Leverage OK-432’s existing safety & efficacy data in NMIBC 1 2 3 4 Explore additional indications / combinations

TARA-002 NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC)

13 TARA-002 in NMIBC: Profile Supports Potential in NMIBC • Urologists have been using an attenuated bacteria, BCG, as immunotherapy for decades • Intravesical administration is preferred clinical approach among urologists (1) • ~150 NMIBC patients tested with OK-432 demonstrated promising results (2) • Treatment generally well tolerated • State-of-the-art manufacturing facility • TARA-002 manufacturing process supported by 40 years of production history of OK-432 • Prompts a predominantly Th1 type cytokine response • Mechanistically similar to BacilleCalmette-Guérin(BCG) MOA Generally Similar to BCG Manufacturing Advantages Promising Existing Clinical Data Modality Familiar with Physicians (1) Market Research Conducted by ProtaraTherapeutics (2) Study references available by request Note: OK-432 is not approved for NMIBC Similar mechanism to BCG, notable patient experience in Asia and manufacturing advantages

Clinical Evidence with OK-432 Provides Strong Rationale for Development of TARA-002 in NMIBC 14 Data across multiple studies in ~150 NMIBC patients treated intravesically shows that OK-432: • Was generally well-tolerated, with safety and tolerability observed across a range of doses • Demonstrated efficacy and lower rates of recurrence vs. control group, including in the randomized, controlled setting FujitaK, et al. Cancer. 1987; 59: 2027-2030 FujitaK, et al. Cancer Detection and Prevention. 1988; 11: 397-403 Sun X, et al. China Journal of Medicine. 2004; 14: 49-54 Liu, Z.H, et al. OncologyLetters. 2017;13:4818-4824. Fujioka et al. Acta Urol. Japan. 1989; 35: 253-257 Study Dose Regimen Total Pts/ OK-432 Pts Efficacy Results Fujita, 1987 Bladder Cancer 2 to 5 KE intratumoral, 5 KE intravesical instillation 78 / 37 In previously unresected tumors, 5 recurrences in OK-432 treated patients vs. 12 recurrences over in the control arm (p<0.05) at 36 months cut off. For patients with primary disease, OK-432 showed a benefit over control in multiple subgroups (multifocal, sessile, or high grade). Fujita, 1988 Bladder Cancer 2 to 5 KE intratumoral, 5 KE intravesical instillation 36 /17 OK-432 reduced recurrence rates of disease (35% recurrence in OK-432 group compared to ~73% recurrence in surgery alone group); OK-432 caused lymphocyte infiltration into carcinomas (as evidenced by histology after resection). Sun and Qiu, 2004 Bladder Cancer 3 KE intravesical instillation weekly for 6 weeks then monthly for 6months 30 / 30 At a mean follow-up of 14 months, tumor recurrence was observed in 16.6% of patients, with no recurrence in 83.4% of patients. OK-432 stimulated secretion of IL-2 and TNFa (p<0.05 for both). Liu et al., 2017 NMIBC 3 KE (in 30 ml) intravesical instillation 55 / 55 Overall, patients treated in the study had a recurrence rate of 34.5% and progression rate of 10.9%. Treatment with OK- 432 was more effective when patients were negative for PD- L1 (16.7% recurrence rate, 4.2% progression rate), regardless of disease stage/grade. Fujioka et al., 1989 NMIBC 5 KE (intravesical), 10 KE (intratumoral) 38 / 38 Tumors were eliminated endoscopically in 6 of 28 (21.4%) patients in which OK-432 was intravesically instilled [Stage Ta = 5 patients, Stage T1 = 1 patient; all patients Grade 1], and 3 of 10 (30%) patients with intratumoralOK-432 injection.

15 BCG Shortage Causes Significant Impact on Care Shortage has prompted major urological associations to issue guidance on patient management (1) “…remain extremely concerned about this shortage and its effects on the care of bladder cancer patients…” -Joint Statement on BCG Shortage, Feb 2019 “I see patients every week whose treatment decisions are affected by the BCG shortage…sometimes I just recommend moving patients more quickly to cystectomy because we don’t have any better options available.” -Academic Hospital Urologist Dose rationing and resorting to less desirable treatment options are impacting patient care (2) BCG shortages begin after Sanofi lab is shut down due to mold infractions Sanofi production of BCG resumes Sanofi announces discontinuation of TheraCysBCG; Merck becomes sole US provider of BCG Merck announces anticipated BCG supply constraints despite expanding capacity 2012 20202013 2014 2015 2016 2017 2018 2019 Merck announces shortages of Tice strain of BCG = BCG Shortage US Urologists are continuing to ration BCG doses and adjust treatment decisions due to shortage (1) AUA/SUO Joint Guideline: Published 2016; Amended 2020 (2) Market Research Conducted by ProtaraTherapeutics

TARA-002 in NMIBC: Overview of U.S. NMIBC & Target Population 16 5% Metastatic 15% Locally Advanced 80% NMIBC (2) Risk Stratification (4) High Risk Intermediate Risk Low Risk Treatment Guidelines TURBT + BCG Mix of TURBT + Chemo/BCG TURBT + Chemo Goal of Treatment 1) Prevent Progression 2) Prevent Cystectomy 3) Prevent Recurrence (1) National Cancer Institute, SEER Cancer Stat Facts: Bladder Cancer, 2019 (2) Anastasiadis et al. Therapeutic Advances in Urology, 2012 (3) Market Research Conducted by ProtaraTherapeutics (4) American Urological Association risk stratification classifies some high-grade tumors as intermediate risk NMIBC is categorized and treated based on risk stratification, determined by combination of tumor grade, stage, size, recurrence history and focality 80K Patients Diagnosed with Bladder Cancer Annually (1) 65K Patients with NMIBC (2) Initial Protara targeted patient population: ~30K (1)(2)(3) Patients with High Grade NMIBC who are candidates for immunotherapy Grading 55% Low Grade (1)(3) 45% High Grade (1)(3) (4)

17 TARA-002 in NMIBC: Highlights of PIND FDA Interaction CMC: ▪ Initial comparability established –GMP scale up in process to complete full comparability testing ▪ Modernized release criteria for large scale (3 batch) comparability Non-Clinical: ▪ Aligned on 6-week local (intravesical instillation) toxicology design with recommendations for IND content preparation ▪ Requested MOA characterization & immunogenicity studies Phase 1: ▪ Initial dose escalation in papillary patients ▪ Clear to enroll CIS patients in Phase 1 Phase 2 ▪ Support for study in CIS patients ▪ Obtained alignment on clinically meaningful endpoints ▪ Papillary patient study suggested comparator to be a chemotherapeutic agent Supportive feedback on multiple facets of NMIBC program

18 TARA-002: State of the Art and Scalable GMP Manufacturing x Successful propagation of working cell bank (WCB) from Chugai OK-432 MCB x TARA-002 WCB -Confirmation of no genetic drift x Modernization of manufacturing and testing techniques (potency, purity, quality attributes) x Proof of concept established with >10 TARA-002 consecutive lots successfully manufactured to date x 3 million vial/year capacity with easy expansion of production

TARA-002 in NMIBC: Estimated Development Timeline 19 2023 •Complete GMP scale up and comparability •Complete non- clinical studies •Initiate Phase 1 study* •Engage International regulatory authorities •Further FDA engagement (SPA request, Fast Track, etc.) 2022 2021 2020 • Initiate GMP scale comparability • Initiate agreed-to non-clinical studies •Complete Phase 1 study •Commence CIS cohort of Phase 2 study •Commence enrollment of Papillary randomized study •Futility analysis in CIS cohort •Topline efficacy in CIS patients *Subject to acceptance of IND filing

TARA-002 LYMPHATIC MALFORMATIONS (LMS)

21 TARA-002 in LMs Epidemiology: incidence of lymphatic malformations is ˜1,400-1,800 LM cases per year (2) Epidemiology Current treatment options include surgical excision with high complication (33%) and recurrence (55%) rates (3) as well as off- label use of sclerosants Current Treatment Options Majority of LMs present at birth (65-75%) or by age 3 (80-90%) during active lymphatic growth period (3) FDA Granted Pediatric Rare Disease Designation Rare, non-malignant lesions consisting of dilated, lymphatic fluid-filled sacs caused by abnormal development of the lymphatic endothelial system (1) Lymphatic Malformations (1) Brouillard P, et al. J Clin Invest. 2014;124:898-904. (2) Internal company estimates (3) Ha J, et al. Curr Ped Rev. 2014;10:238-248.

Before After 22 OK-432 in LMs: Clear Evidence of Biologic Activity in Patients Before After ProtaraTherapeutics data on file

23 OK-432 in LMs: Robust Results of Completed Phase 2 Study (1) inU.S. 68% 0% Immediate Treatment Group (N=91) Delayed Treatment Group Pre- Treatment** (N=26) ITT: Observations 6 months after enrollment 68% CLINICAL SUCCESS ? IN IMMEDIATE TREATMENT GROUP 6 MONTHS AFTER ENROLLMENT • Patients with radiographically confirmed appropriate lesions had the greatest chance for clinical success • In those patients with mixed lesions, clinical success was still achieved 94% * CLINICAL SUCCESS ? IN PATIENTS WITH MACROCYSTICLESION TYPES 71% 25% 22% 38% 0% Macrocystic Lymphangiomas (n=79) Mixed (n=40) Microcystic Lymphangiomas (n=17) Complete or Substantial Response by Radiographically Confirmed Lesion Type Complete Response Substantial Response 94% * 63% ? Clinical Success was defined as complete or substantial response *Numbers do not sum due to rounding **Reflects data prior to dosing with OK-432. After dosing, the clinical success rate was 58%, which was not statistically different from the Immediate Treatment Group (1) Smith M, et al. Laryngoscope. 2009;119:107-115. • None of these patients required surgery • During this same period, no patients in the delayed treatment group experienced spontaneous regression of LM (p<0.001) • Treatment: 1-4 injections at 8-week intervals max of 0.2mg/session (2KE)

Smith M, et al. Laryngoscope. 2009;119:107-115. Safety Profile ▪ Most common AEs with treatment were local injection site reactions, fever, fatigue, decreased appetite, with resolution within two weeks ▪ SAEs relatedto OK-432: re-hospitalization for infection (n=3) and severe edema (n=3), airway obstruction necessitating tracheostomy tube placement (n=4), and submental intra-cystic hemorrhage necessitating surgical excision (n=1) ▪ Minor AEs relatedto OK-432: temporary brachial plexus compression, myalgia, infections treated with oral antibiotics, intra-cystic hemorrhage, and dehydration ▪ Two SAEs not related to OK-432: death due to tracheotomy tube obstruction and vision loss following proptosis Long-term safety data in 99 patients with up to 8 years of follow up OK-432 in LMs: Compelling Safety Record 24

TARA-002 in LMs: Planned Next Steps If additional registrational study required – Launch in the US – File marketing applications in EU countries 2023 – Complete study – Submit BLA – US Approval Q3’2022 2022 – Complete GMP comparability – Initiate enrollment of study (mid-2021) – Engage European regulators 2021 – Complete IND update (Iowa Data, comparability, etc.) – Apply for Fast-track – Agree with FDA on design of any additional study* 2020 – Launch in the EU and other international geographies 2023 – Launch in the US – File marketing applications in the EU 2022 – Complete GMP comparability – Engage European regulators – Submit BLA (mid-2021) – US Approval (Q4’2021) 2021 – Complete IND update (Iowa Data, OTAT comparability, etc.) – Apply for Fast-track – Agree with FDA no study needed* 2020 If current data set sufficient for BLA/MAA submission 25 *Company intends to request meeting with FDA by year end

IV CHOLINE CHLORIDE INTESTINAL FAILURE ASSOCIATED LIVER DISEASE (IFALD)

27 IV Choline in IFALD: Late-stage Opportunity for an Unmet Medical Need A Phase 2 study demonstrated the clinical potential of choline substrate replacement therapy by reversing certain hallmark pathologies of IFALD (1) Clinical History Supporting Choline Substrate Replacement in IFALD (intestinal failure associated liver disease) Patients Prevalence of patients on PN 79/million (2) ; recent Medicare diagnosis data suggests ˜ 5,000 IFALD patients (3) Strong Market Opportunity with Potential to Expand Addressable Patients FDA designations (Orphan Drug Designation, Fast Track Designation) combined with encouraging feedback from End of Phase 2 meeting for Phase 1 PK study followed by Phase 3 trial Clear Regulatory and Clinical Path Forward Patients dependent on Parenteral Nutrition (PN) cannot absorb sufficient levels of choline. Data confirms that choline deficient diets results in steatosis and cholestasis (1) An Essential Molecule in Several Metabolic Processes (1) Buchman A, et al. JPEN. 2001;5:260-268. (2) Mundi M, et al. ASEPN. 2017;32:799-805. (3) Internal Protara market research

IV Choline in IFALD: Informative Clinical History A significant body of supportive evidence across 4 studies 1992 -Oral Lecithin Study (1) n=15 PN patients Lecithin did not achieve physiologic levels; however did reduce steatosis with moderate ALP* improvement 1994 -IV PK Study (2) n=4 PN patients 1st continuous exposure to IV choline, established safety and 2g dose 1995 -IV Pilot Study (3) n=4 PN patients IV Choline replacement reversed steatosis, improved other measures of hepatobiliary injury 2001 -IV Phase 2 RCT (4) n=15 PN patients 2g dose confirmed, reversal of steatosis, improvement in cholestasis (reduction of ALP*) 1) Buchman A, et al. Gastroenterology. 1992;102:1363-1370. 2) Buchman A, et al. Clin PharmacolTher. 1994;55:277-283. 3) Buchman A, et al. Hepatol. 1995;22:1399-1403. 4) Buchman A, et al. JPEN. 2001;5:260-268. 28 * ALP=Alkaline phosphatase

IV CHOLINE REPLACEMENT PROOF OF CONCEPT STUDY (1) Study Design Randomized Double-blind Phase 2 Trial Subjects 15 (9 per protocol) Age >16 years old PN Requirement Greater than 80% of all nutrient requirements supplied by PN Randomization 1:1 Usual PN or PN + 2g IV choline/Day Duration of Treatment 24 Weeks Visits Weeks 2,4,6,12,16, 20, 24 Follow up Week 34 Dose 2g Choline Chloride QD in PN solution ▪ The IV Choline Chloride replacement proof-of-concept, randomized study did not have pre-specified endpoints ▪ The primary objective of the study was to determine if IV Choline Chloride substrate replacement would reverse hepatic steatosis and improve liver function in patients receiving long-term parenteral nutrition (PN) Randomized, Controlled Study Design & Objective IV Choline in IFALD: Multi-Center Phase 2a POC Study 29 1) Buchman A, et al. JPEN. 2001;5:260-268.

IV Choline in IFALD : Phase 2 Results 30 CHOLESTASIS IMPROVEMENT: ALL PATIENTS* (1) CLINICALLY MEANINGFUL IMPROVEMENT IN STEATOSIS At Baseline After 24 Weeks *Mixed model for repeated measurement (MMRM) method used ?Aplacebo subject was excluded from all analyses due to likely IV contrast-induced imaging abnormalities, confirmed by independent radiologist n=14?(7 active; 7pbo) (1) Protara Therapeutics re-analysis of patient CRF’s, data on file Improvement in Steatosis and Cholestasis

31 IV Choline in IFALD: Prevalence Study Prevalence study to be conducted to enhance understanding of the patient population DESIGN Retrospective, observational study of patients in both academic & community settings POPULATION Patients dependent on PN for 6 or more months OBJECTIVE Understand presence/incidence of liver disease in this population to enhance value of development potential QUESTIONS How many individuals currently on service have been dependent on PN for 6 or more months? What percentage of these have elevated ALP levels (> 1.5x ULN) as an indicator of liver disease?

FINANCIAL OVERVIEW

Finance Overview 33 FINANCING HISTORY $30M Cash position as of June 30, 2020 9.7M Common Share Equivalents 5.9M Common plus 3.8M Preferred on as-converted basis (as of June 30, 2020) Date Type $M Investors 2017 Seed Round $3 Founders, friends & family 2017-18 Series A $5.5 Smaller dedicated life sciences funds 2020 PIPE/Reverse Merger $42.5 Global dedicated life sciences funds OPERATIONS

Key Projected Milestones 34 TARA-002—NMIBC 2020 1H21 2H21 1H22 Results of Non-clinical Studies Initiate Phase 1 Study* Initial Pharmacodynamic Data from Phase 1 Phase 1 Study Completion TARA-002—LMs 2020 1H21 2H21 1H22 Fast Track Granted Request Meeting with FDA to Discuss Next Steps BLA Submission** US Commercial Launch** Completion of Confirmatory Arm** TARA-002 General 2020 1H21 2H21 1H22 FDA Agreement on Initial Comparability with OK-432 Results of Characterization and Syngeneic Mouse Model Studies GMP-scale Comparability Results *Subject to acceptance of IND filing **Assumes conditional approval granted following first five patients in LMs study if required

35 Investment Summary Lead programs: TARA-002 in Non-Muscle Invasive Bladder Cancer (NMIBC) and Lymphatic Malformations (LMs) • Cell-based immunopotentiator • FDA confirmed initial comparability to Japanese predecessor OK-432 • NMIBC clinical development plan in place following Pre-Investigational New Drug (PIND) engagement with FDA • TARA-002/OK-432 is standard of care in Japan for LMs; completed Phase 2 study in US supports treatment effect with strong safety profile Entrepreneurial team with demonstrated history of uncovering and accelerating overlooked assets Other mid-stage development programs provide diversification and additional growth potential • IV Choline in intestinal failure associated liver disease (IFALD): Completed End Of Phase 2 dialogue with FDA and aligned on Phase 3 design

APPENDIX

OK-432 in LMs: Overview of Completed Phase 2 Study Randomized, Controlled Study (N=117) (1) Age 6 months –18 yrs Inclusion Criteria LMs of the head and/or neck confirmed by MRI or CT ▪ Radiographically confirmed macrocystic LM or mixed macrocystic-microcystic LM with >50% macrocystic component At least 6 months since prior surgery for lymphangioma Exclusion Criteria Penicillin allergy, pregnancy and/or nursing, personal or family history of rheumatic heart disease, post-streptococcal glomerulonephritis, PANDAS, history of significant cardiac, pulmonary, hepatic, renal, or hematologic disease Treatment Groups Immediate Treatment Group (ITG): Received OK-432 shortly after enrollment Delayed Treatment Group (DTG): Observed for 6 months for spontaneous regression, then treated with OK-432 Open Label Group (OLG):nonrandomized, included infants <6 months, adults >18 yrs, patients with LMs in sites other than the head/neck, and patients treated on an emergent basis Randomization 2:1 Randomization (per blocks of 6 enrollees) 2/3 in ITG and 1/3 in DTG (control group) Duration of Treatment 1-4 injections 8 weeks apart Dose Max of 0.2mg/session (i.e. 2 KlinischeEinheit) (1) Smith M, et al. Laryngoscope. 2009;119:107-115. Primary Endpoint: Response to treatment in the ITG compared to the spontaneous resolution rate observed in the DTG, 6 months after enrollment Definition of Response Response to therapy was measured radiographically (MRI or CT) by quantitating change in lesion size and graded as: • Complete (90%–100%), • Substantial (60%–89%), • Intermediate (20%–59%), • None (<20%) Secondary Endpoints: 1) The proportion of ITG patients versus DTG patients who demonstrated a complete response (90%–100%) 6 months following enrollment 2) The proportion of randomized patients who demonstrated at least a substantial response (60%– 100%) greater than 6 months following the last injection (i.e. persistence of response) 3) The proportion of patients in the OLG who demonstrated at least a substantial response (60%– 100%) 6 months following enrollment and 6 months following the last injection (i.e. persistence of response) 37

Completers (N=119): Completed all protocol visits, received up to 4 injections and evaluated 14 days after last injection, includes non-randomized Open Label Group Patient Demographics Group Patients Enrolled (n=182) Patients Randomized Completing Treatment (n=92) Open Label Group Completing Treatment (n=27) Sex (F:M) 92 : 90 42 : 50 15 : 12 Age Range (years) 0-73.1 0.5-15.5 0-73.1 Mean/median age (years) 5.8/1.7 3.5/2.1 13.4/1.1 Race Demographics Caucasian 133 74 20 African- American 15 8 2 Asian-Pacific Islander 14 4 4 Hispanic 10 6 1 Unknown 10 182 patients enrolled in study 31 patients Incomplete case report forms and imaging or lost to follow up 151 patients Complete case report forms and imaging 117 patients Randomized with intent to treat 91 patients Immediate Treatment Group (ITG) 26 patients Delayed Treatment Group (DTG) 72 patients Completed treatment 20 patients Completed treatment 27 patients Completed treatment 34 patients Open Label Group 2 2 2 2 Intent-to-Treat (N=117): Randomized, completed visits to first 6 months 1 1 OK-432 in LMs: Patient Disposition of Completed Phase 2 Study (1) 2:1 randomization 38 (1) Smith M, et al. Laryngoscope. 2009;119:107-115.

CorporatePresentation September2020